Druggability & Clinical Context
Druggability
Low
Score: 0.36
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
13
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Druggability Rationale: Based on the available data, NTN1 presents challenges for traditional small molecule drug discovery due to its complex protein-protein interaction role in neuronal pathways. While recombinant Netrin-1 shows preclinical potential and structural models are available, the target's low druggability suggests that alternative approaches like biologics, peptide mimetics, or targeted protein engineering may be more promising for neurodegeneration therapeutic strategies. The limited clinical trial evidence and structural complexity indicate that further research is needed to validate NTN1 as a viable therapeutic target.
Mechanism: Modulation of axon guidance and neuronal survival pathways
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:Recombinant Netrin-1 (preclinical) — Axon guidance factor, neuroprotective in ischemia models
Structural Data:PDB (13) ✓AlphaFold ✓Cryo-EM ✓
Selectivity & Safety Considerations
Netrin-1 acts through multiple receptors (DCC, UNC5A-D), creating potential off-target liabilities; selectivity would need to consider whether modulating NTN1 broadly or achieving receptor-specific signaling is desired. The secreted nature and broad tissue distribution of NTN1 present challenges for achieving CNS selectivity without systemic exposure.